Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria

References

• Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol.71, 968–980 (2006).
   PubMed Web of Science ®Google Scholar
• Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother.55(Suppl. S2), ii15–ii20 (2005).
   PubMed Web of Science ®Google Scholar
• Jones RN, Streit JM, Fritsche TR. Validation of commercial dry-form microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int. J. Antimicrob. Agents23, 197–199 (2004).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Johnson AP et al. Activity of dalbavancin against staphylococci and streptococci assessed by BSAC and NCCLS agar dilution methods. J. Antimicrob. Chemother.54, 617–620 (2004).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Rennie RB, Goldstein BP et al. Comparison of dalbavancin MIC values determined by Etest (AB Biodisk) and reference dilution methods using Gram-positive organisms. J. Clin. Microbiol.44, 2988–2990 (2006).
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Ross JE, Fritsche TR et al. Activity of dalbavancin against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol.45, 998–1004 (2007).
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Fritsche TR et al. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol.44, 2622–2625 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez S, Hackbarth C, Romano G et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J. Antimicrob. Chemother.55(Suppl. S2), ii21–ii24 (2005).
   PubMedGoogle Scholar
• Streit JM, Fritsche TR, Sader HS et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis.48, 137–143 (2004).
   PubMed Web of Science ®Google Scholar
• Jones RN, Stiwell MG, Sader HS et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States surveillance program. Diagn. Microbiol. Infect. Dis.54, 149–153 (2006).
   PubMed Web of Science ®Google Scholar
• Streit JM, Sader HS, Fritsche TR et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis.53, 307–310 (2005).
   PubMed Web of Science ®Google Scholar
• Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect.11, 95–100 (2005).
   PubMed Web of Science ®Google Scholar
• Lin G, Credito K, Ednie LM et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother.49, 770–772 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Merriam CV et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob. Agents Chemother.47, 1968–1971 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Warren YA et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother.50, 2875–2879 (2006).
   PubMed Web of Science ®Google Scholar
• Lin G, Smith K, Ednie LM et al. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob. Agents Chemother.49, 5182–5184 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein BP, Draghi DC, Sheehan DJ et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob. Agents Chemother.51, 1150–1154 (2007).
   PubMed Web of Science ®Google Scholar
• Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J. Antimicrob. Chemother.58, 802–805 (2006).
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Esel D, Whitener C et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother.52, 864–868 (2003).
   PubMed Web of Science ®Google Scholar
• Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother.58, 627–631 (2006).
   PubMed Web of Science ®Google Scholar
• Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis.37, 1298–1303 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson DM, Fritsche TR, Sader HS et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int. J. Antimicrob. Agents27, 557–560 (2006).
   PubMed Web of Science ®Google Scholar
• Denis O, Nonhoff C, Deplano A et al. In vitro activity of ceftobiprole, dalbavancin and tigecycline against methicillin-resistant Staphylococcus aureus strains from hospitalised patients in Belgium. Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Disease. Munich, Germany, Abstract P784 (2007).
   Google Scholar
• Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother.50, 1581–1585 (2006).
   PubMed Web of Science ®Google Scholar
• Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother.50, 1079–1082 (2006).
   PubMed Web of Science ®Google Scholar
• Dorr MB, Jabes D, Cavaleri M et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother.55(Suppl. S2), ii25–ii30 (2005).
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother.51, 1633–1642 (2007).
   PubMed Web of Science ®Google Scholar
• Jabes D, Candiani G, Romano G et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob. Agents Chemother.48, 1118–1123 (2004).
   PubMed Web of Science ®Google Scholar
• Lefort A, Pavie J, Garry L et al. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob. Agents Chemother.48, 1061–1064 (2004).
   PubMed Web of Science ®Google Scholar
• Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect.50, 206–209 (2005).
   PubMed Web of Science ®Google Scholar
• Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J. Clin. Pharmacol.45, 1279–1287 (2005).
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother.48, 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Solon EG, Dowell JA, Lee J et al. Distribution of radioactivity in bone and related structures following administration of [14C]-dalbavancin to New Zealand white rabbits. Antimicrob. Agents Chemother. doi:10.1128/AAC.00020-07 (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vasquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis.40, 374–380 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein BP, Jones RN, Fritsche TR et al. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn. Microbiol. Infect. Dis.54, 83–87 (2006).
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis.41, 1407–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Carmeli T, Rothermel C, Sheehan D et al. Analysis of patients with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in a phase 3 study of dalbavancin vs. linezolid for the treatment of complicated skin and soft tissue infections (CSSTI). 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 27–30 September (2006).
   Google Scholar
• Campbell KC, Kelly E, Targovnik N et al. Audiologic monitoring for potential ototoxicicty in a phase I clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol.14, 157–168 (2003).
   PubMedGoogle Scholar
• Lye D, Athan E, O’Brien D. Teicoplanin hypersensitivity syndrome. Int. J. Antimicrob. Agents29(4), 476–478 (2007).
   PubMed Web of Science ®Google Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol.44, 3883–3886 (2006).
   PubMed Web of Science ®Google Scholar
• Tenover FC, Moellering RC. The rationale for revising the CLSI vancomycin minimal inhibitory concentration interpretative criteria for Staphylococcus aureus. Clin. Infect. Dis.44, 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Wooton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol.45, 329–332 (2007).
   PubMed Web of Science ®Google Scholar
• Ruhe JJ, Smith N, Bradsher RW et al. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin. Infect. Dis.44, 777–784 (2007).
   PubMed Web of Science ®Google Scholar
• Gorwitz RJ. The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.44, 785–787 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis MW, Lewis JS. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis.18, 496–501 (2005).
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest130, 947–955 (2006).
   PubMed Web of Science ®Google Scholar
• Dumitrescu O, Boisset S, Badiou C et al. Effects of antibiotics on S. aureus producing Panton-Valentine leukocidin. Antimicrob. Agents Chemother.51, 1515–1519 (2007).
   PubMed Web of Science ®Google Scholar